Phase IIa Trial of Oral SSS17 for Post-Arthroplasty Anemia

Inclusion criteria

• Signed informed consent obtained

-

• Age 18-70 years (inclusive)

-

• Candidates for hip/knee arthroplasty

-

• No DVT on pre-op venous ultrasound

-

• Screening Hb 80-110 g/L (no transfusion indication) - 6. Commitment to effective contraception

Exclusion criteria

• Hypersensitivity to the investigational product or any of its components
• Any other condition causing chronic anemia
• Coagulopathy or unstable anticoagulant dosing during screening
• Any of the following laboratory abnormalities at screening:

• Serum albumin <35 g/L
• ALT or AST >3×ULN
• Active infections or carrier status including:

• Known HIV infection
• Active syphilis
• Active HBV infection (HBsAg-positive with HBV DNA >10³ copies/mL)
• Active HCV infection (anti-HCV positive with detectable HCV RNA)
• Acute joint injury with active trauma or infection at screening
• Cognitive impairment or psychiatric disorders,current or history of epilepsy
• Treatment with ESAs (erythropoiesis-stimulating agents) or HIF inhibitors within 30 days prior to dosing
• History of severe thromboembolic events or hematopoietic disorders
• Malignancy history
• Severe cardiovascular diseases including:

• Unstable coronary artery disease
• Heart failure (NYHA Class III/IV)
• Myocardial infarction/stroke 12 .Poorly controlled hypertension

• Alcohol abuse 14.Pregnancy or lactation 15.Participation in other drug trials within 3 months prior to enrollment 16.Any other condition deemed by the Investigator to compromise subject safety or trial validity